LUAD is frequently associated with mutations in EGFR, KRAS, ALK, and BRAF, while LUSC is more commonly linked to alterations ...

The Rybrevant-Lazcluze combo significantly reduced the risk of death by 25% versus Tagrisso in patients with newly diagnosed advanced EGFR-mutated NSCLC, according to data from the phase 3 ...

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib.

Lazertinib is an oral, highly selective, third-generation EGFR tyrosine kinase inhibitor that can penetrate the brain, and amivantamab is a bispecific antibody targeting EGFR and mesenchymal ...